Norstella’s Real-World Data/AI Executive Forum highlights

Run time

1 minute, 48 seconds

The Norstella Real-World Data Executive Forum explores how real-world data (RWD) can accelerate treatment progress in neuro-oncology, particularly for small patient populations and rare subgroups whose outcomes take years to fully measure. Norstella’s mission to “smooth the path to life-saving therapies” guides its RWD strategy, including curating data elements that closely mirror clinical trial inclusion and exclusion criteria. Speakers highlight the emergence of “next-gen RWD,” which integrates unstructured data through large language models, and emphasize that the value of abundant data depends on how effectively it is transformed and applied. AI is identified as a key enabler, with investigator selection cited as a prime use case for combining RWD and AI. The forum underscores the need to build a community skilled in leveraging these data and tools, with the shared goal of improving patient lives “one insight, one data set, and one story at a time.”

View video transcript

Welcome to the Norstella Real-World Data Executive Forum.

Why is real-world data important to the patient population in neuro-oncology where patient numbers are small and the outcomes take years to fully measure insights from the real-world data can provide dramatically accelerated progression for treatment, for rare subgroups that might otherwise go unseen.

Our corporate mission at Norstella is all about smoothing the path to life-saving therapies. This is really what guides us in our approach to all things we do, but especially with RWD.

We are able to curate these data elements that mimic the majority of the inclusion-exclusion criteria from your trial.

We need to add that foundation to be able to explain why this data that we’re generating matters and why we’re continuing our development program.

Next-gen RWD, I would say, is wonderfully complex in the sense that you’re bringing in all this unstructured data with your large language models.

AI, it’s a big word. Everybody’s talking about it.

The amount of data we have I think is a huge benefit, but that data’s only going to be useful for how useful we make it and how we can transform it.

Investigator selection, I think, is an area that is just prime for help, both from RWD, but also from AI.

I think we are going to see over the next few years a tremendous opportunity to leverage all this data, to build a community of people who understand how to use it.

I know together we can keep pushing forward to improve patient lives, one insight, one data set, and one story at a time.

Frequently asked questions

What is real-world data (RWD) and why is it important in neuro-oncology?

Real-world data helps researchers uncover insights from patient populations that are often too small or complex to study through traditional methods alone. In neuro-oncology, RWD can accelerate understanding of treatment outcomes and identify trends in rare patient subgroups that may otherwise go unnoticed.

How does real-world data support faster treatment development?

RWD provides earlier visibility into patient outcomes, treatment patterns, and disease progression. By supplementing traditional clinical research, it can help life sciences organizations make more informed development decisions faster.

How does Norstella use real-world data to support life sciences organizations?

Norstella curates and connects complex healthcare datasets to help organizations generate actionable insights, support evidence generation, and advance therapies that improve patient outcomes.

Why is unstructured data important in next-generation RWD?

Unstructured data—such as clinical notes, pathology reports, and physician narratives—contains valuable patient insights that are often unavailable in structured claims or EMR fields. Advances in AI and large language models are making it easier to extract and analyze this information at scale.